Content
Search
Navigation
Sitemap
About us
Pipeline & science
Overview
Obesity
Type 2 Diabetes Mellitus (T2DM)
Acute Ischemic Stroke (AIS)
Hypertension
Our expertise
Overview
Our strategic partners
Global opportunities
Join us
Press releases
Contact
简体中文
Search
简体中文
Navigation
Press releases
16 Feb 2022
JIXING Announces Receipt of Breakthrough Therapy Designation for Aficamten in China
Read article
04 Feb 2022
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction
Read article
20 Dec 2021
Cytokinetics and JIXING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
Read article
03 Dec 2021
JIXING Completes Phase 1 Study of Aficamten, a Potential Next-generation Cardiac Myosin Inhibitor, for Patients with Hypertrophic Cardiomyopathy (HCM)
Read article
19 Nov 2021
JIXING Announces IND Approval for Phase 1 and Phase 3 Clinical Trials of Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PSVT) in China
Read article
05 Aug 2021
Oyster Point Pharma Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China
Read article
Load more
